02488nas a2200253 4500000000100000008004100001653001400042653002400056653003000080653003900110653001900149653003500168653001300203653001700216100001400233700001400247700001200261245015100273856007300424300001400497490000700511520170200518022001402220 2017 d10aTreatment10aTraditional recipes10aPlant species of interest10aNeglected tropical diseases (NTDs)10aMedical plants10aEthnopharmacological reasoning10aCameroon10aBuruli ulcer1 aBayaga HN1 aGuedje NM1 aBiye EH00a[Ethnopharmacological and ethnobotanical approach of medicinal plants used in the traditional treatment of Buruli ulcer in Akonolinga (Cameroon).] uhttps://www.ajol.info/index.php/ijbcs/article/download/164026/153514 a1523-15410 v113 a

Few data are available concerning plants used in the traditional treatment of Buruli ulcer in Cameroon. This study aimed to identify species and characterize anti-Buruli ulcer recipes in the Akonolinga district. The ethnopharmacological survey has enabled to identify 25 plant species used against Buruli ulcer. The plant parts mostly used were stem bark (41.1%), stem (26.8%) and leaves (25%). Decoction (64.3%) and pounding (23.2%), the most dominant preparing method, were administrated externally, mostly by massage and disinfection (64.3%) and by local poultice application (14.3%). The analysis of relative frequency of citation, as well as the search of similarity and convergence of use, have shown that Musa parasidiaca, Mitracarpus villosus, Aframomum melegueta, Elaeis guineensis and Spathodea campanulata were among species exhibiting remarkable convergence of use between different geographical regions; while seven others, Petersianthus macrocarpus, Momordica spectabilis, Citrus medica, Terminalia superba, Ceiba pentandra and Ipomoea aquatica, formed another most significant species group.In highlighting those 12 species of interest, this study has direct bearing in drug design and innovation by the ethnopharmacological reasoning, thereby contributing to species selection and direction for prior chemical, pharmacological and clinical assessments leading to plant-based drug development that Africa needed for its pandemic pathologies.

 a1991-8631